Deals in Depth: November 2010
Executive Summary
Surprisingly no Big Pharmas or top biotech companies were party to the biggest alliances. Instead German drug maker Grunenthal won out, selling its oral contraceptives portfolio to Gedeon Richter for $331 million. Both valued at $800 million, Lilly's acquisition of Avid ($300 million up front plus $500 million in earn-outs) and Medtronic's takeover of Ardian tied for the top spots in the M&A category. FOPOs were the most lucrative vehicle in pharma and device fundraising, with each industry bringing in over $200 million from this financing type.